Longeveron Inc.

LGVN | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.53

+$0.08 (+3.27%)

Sep 22, 2026, 12:56 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+3.27%

(1D)

Rating

Updated: Sep 12, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $7.7M

1D Range

2.32 2.55

52W Range

2.30 12.30

Valuation (TTM)

PE -2.43

PB 0.72

EV/EBITDA 0.09

Valuation (NTM)

Forward PE N/A

Forward PEG 0.01

Price Target $10

Cash Flow

FCF Yield -277.1%

SBC Adj. FCF Yield -298.2%

SBC Impact -7.6%

Margins

Gross Margin 69.8%

Operating Margin -1992.8%

FCF Margin -1740.4%

Growth (CAGR)

Revenue 3Y | 5Y 12.2% | -21.2%

Dil EPS 3Y | 5Y 105.4% | 40.7%

FCF 3Y | 5Y -10.9% | -9.8%

Returns

ROA -151.6%

ROE -223.2%

ROIC -201.1%

Financial Health

Net Cash

$10.08M

Current Ratio 2.63

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditio...

Sector Healthcare

Industry Biotechnology

Employees 38

IPO Date Feb 11, 2021

Website www.longeveron.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 3, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$10

Upside

+295.26%

Buy (1)

Hold (1)

Sell (0)

Analyst Details ➞